Enliven Therapeutics (NASDAQ: ELVN)
$19.98
(5.8%)
$1.10
Price as of August 13, 2025, 4:00 p.m. ET
Enliven Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Enliven Therapeutics Company Info
Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates. The company was founded in June 2019 and is headquartered in Boulder, CO.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.